Journal
ONCOIMMUNOLOGY
Volume 6, Issue 8, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2017.1338235
Keywords
chordoma; brachyury; immunotherapy; immune checkpoint inhibitors; melanoma antigens; neoantigen; tumor vaccine
Categories
Funding
- l'Association Marietta, le Fond Lionel Perrier, l'Association Frederic Fellay, Fond'action
- la Ligue genevoise contre le Cancer
Ask authors/readers for more resources
Chordoma is a rare tumor of notochordal origin, currently principally treated by surgery and/or irradiation. Here, we describe the clinical outcome of 3 consecutive patients with metastatic and locally advanced chordoma, treated with different immunotherapeutic approaches. All patients presented fast growing tumors and failure of standard therapies. One was treated with a tumor-based vaccine, the 2 others with anti-PD1 antibodies, all with impressive clinical and radiological responses. We therefore propose that chordoma is an immunogenic tumor and thus that translational and clinical research is necessary to develop rationally designed immunotherapy approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available